e-learning
resources
2021
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Duration of rheumatoid arthritis and the risk of developing interstitial lung disease
Michael P. Mohning, Isabelle Amigues, M. Kristen Demoruelle, Evans R. Fernández Pérez, Tristan J. Huie, Rebecca K. Keith, Amy L. Olson, Zulma X. Yunt, Jonathan H. Chung, Stephen Hobbs, Jeffrey J. Swigris, Joshua J. Solomon
Source:
ERJ Open Res, 7 (1) 00633-2020; 10.1183/23120541.00633-2020
Journal Issue:
January
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Michael P. Mohning, Isabelle Amigues, M. Kristen Demoruelle, Evans R. Fernández Pérez, Tristan J. Huie, Rebecca K. Keith, Amy L. Olson, Zulma X. Yunt, Jonathan H. Chung, Stephen Hobbs, Jeffrey J. Swigris, Joshua J. Solomon. Duration of rheumatoid arthritis and the risk of developing interstitial lung disease. ERJ Open Res, 7 (1) 00633-2020; 10.1183/23120541.00633-2020
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
ERS statement for defining respiratory exacerbations in children and adolescents with bronchiectasis for clinical trials
Related content which might interest you:
Risk factors of interstitial lung diseases in patients with rheumatoid arthritis.
Source: International Congress 2019 – Immune-mediated interstitial lung diseases: from bench to bedside
Year: 2019
Mortality and clinical features in rheumatoid arthritis and interstitial lung disease
Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment
Year: 2017
Interstitial lung disease in patients with rheumatoid arthritis
Source: Annual Congress 2008 - Sarcoidosis and other interstitial lung diseases
Year: 2008
Predicting outcomes in rheumatoid arthritis related interstitial lung disease
Source: Eur Respir J, 53 (1) 1800869; 10.1183/13993003.00869-2018
Year: 2019
Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease
Source: Eur Respir J 2016; 47: 588-596
Year: 2016
Methotrexate and rheumatoid arthritis associated interstitial lung disease
Source: Eur Respir J, 57 (2) 2000337; 10.1183/13993003.00337-2020
Year: 2021
Characteristics and predictors of outcome in rheumatoid arthritis related ILD
Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease
Year: 2013
Interstitial lung abnormalities a risk factor for rheumatoid arthritis interstitial lung disease progression: what's new
Source: Breathe, 16 (4) 200223; 10.1183/20734735.0223-2020
Year: 2020
Rituximab improves interstitial lung disease in rheumatoid arthritis patients
Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment
Year: 2017
Infliximab therapy in interstitial lung disease associated with rheumatoid arthritis
Source: Annual Congress 2004 - Fibrosing lung diseases
Year: 2004
Infliximab treatment in patients with interstitial lung disease and rheumatoid arthritis
Source: Eur Respir J 2002; 20: Suppl. 38, 587s
Year: 2002
Analysis of lung diseases associated with rheumatoid arthritis
Source: Eur Respir J 2006; 28: Suppl. 50, 307s
Year: 2006
Co-morbidities and cause of death in patients with rheumatoid arthritis associated interstitial lung disease
Source: International Congress 2015 – Connective tissue disorders
Year: 2015
Are smoking and COPD associated with ILD onset in rheumatoid arthritis?
Source: Virtual Congress 2020 – Predictive markers of progression in connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis
Year: 2020
Pulmonary disease associated with rheumatoid arthritis
Source: Virtual Congress 2021 – Exercise tolerance, supportive care and more in non-pulmonary fibrosis interstitial lung diseases
Year: 2021
The lung in rheumatoid arthritis: drugs versus underlying disease
Source: Annual Congress 2009 - Lung disease in rheumatoid arthritis treated with tumour necrosis factor inhibitors: a pulmonary perspective
Year: 2009
Are risk predicting models useful for estimating survival in rheumatoid arthritis-associated interstitial lung disease?
Source: International Congress 2016 – Connective tissue disorders
Year: 2016
Nintedanib reduces fibrotic markers in the lung in a model of rheumatoid arthritis associated interstitial lung disease
Source: International Congress 2016 – ILD pathogenesis
Year: 2016
The value of biomarkers in the rheumatoid arthritis related interstitial pneumonia
Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease
Year: 2013
Features and functional deterioration in interstitial lung disease (ILD) asociated to rheumatoid arthritis (RA)
Source: International Congress 2019 – Assessment and management of immune-mediated interstitial lung diseases
Year: 2019
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept